Glassman Wealth Services’s Adicet Bio ACET Stock Holding History

Glassman Wealth Services’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29	Closed	-$862	–	221
2023 Q4	$862	Buy	29 +24	+480%	+$523	﹤0.01%	1587
2023 Q3	$110	Buy	+5	New	+$177	﹤0.01%	1964

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glassman Wealth Services's ACET Position: Q1 2024 in Review

Glassman Wealth Services sold out of Adicet Bio (ACET) in Q1 2024, closing a stake of 29 shares — an estimated $862 sold.

Glassman Wealth Services first reported a position in ACET in Q3 2023 and held it in 2 quarters. The position peaked at $862 in Q4 2023. 96 funds tracked by Wall St. Rank hold ACET as of Q1 2024.

Glassman Wealth Services reported no remaining Adicet Bio position as of Q1 2024 after selling out during the quarter.
Glassman Wealth Services sold 29 Adicet Bio shares in Q1 2024, an estimated $862.
Glassman Wealth Services first reported a position in Adicet Bio in Q3 2023 and held it in 2 quarters.
Glassman Wealth Services's Adicet Bio position peaked at $862 in Q4 2023.
96 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.